Results 201 to 210 of about 21,287,561 (278)

Nanoparticles in Vascular Dementia: Advantages and Challenges

CNS Neuroscience &Therapeutics, Volume 32, Issue 6, June 2026.
This review highlights the dual diagnostic and therapeutic potential of nanomaterials in Vascular Dementia (VaD). By effectively crossing the blood–brain barrier, functionalized nanoparticles facilitate early diagnosis by targeting Aβ deposits and vascular lesions.
Xianxin Liu, JiaLi Hu, Yueming qiu, Huaying Wang, Chunxiao Shen, Ziying Liu, Yiting He, Xuefei Du, Xiaorong Zhang   +8 more
wiley   +1 more source

Leptin in Obesity‐Related Heart Failure: Pathophysiological Mechanisms and Therapeutic Implications

Comprehensive Physiology, Volume 16, Issue 3, June 2026.
Obesity‐associated adipose tissue dysfunction leads to hyperleptinemia and altered leptin signaling. Through Ob‐Rb/LepR‐mediated pathways, leptin may contribute to neurohormonal activation, endothelial dysfunction, inflammation, oxidative stress, and myocardial remodeling.
Xuemin Li, Weiguo Wang, Yibo Zhang, Pengfei Ding, Xuewen Li   +4 more
wiley   +1 more source

Pharmacokinetic Drug–Drug Interaction Potential of Oral Anticancer Drugs

Clinical Pharmacology &Therapeutics, Volume 119, Issue 6, Page 1614-1627, June 2026.
Drug–drug interaction (DDI) management is critical for safe and effective use of oral anticancer drugs (OADs). Our study objectives were to (i) compile clinically relevant pharmacokinetic (PK) DDI mechanisms for OADs and (ii) assess the prevalence of PK potential DDIs (PDDIs) in patients with advanced solid cancers.
Fatimah Alhurayri, Islam R. Younis, Shadia I. Jalal, Theodore F. Logan, Rohan Maniar, Steven M. Bray, Sara K. Quinney, Zeruesenay Desta, Todd C. Skaar, James E. Tisdale, Tyler Shugg   +10 more
wiley   +1 more source

Fusobacterium nucleatum in cancer: Interactions with microbiota, tumour colonisation and cancer progression

Clinical and Translational Medicine, Volume 16, Issue 6, June 2026.
F. nucleatum colonises tumours through mucosal translocation, adjacent‐tissue migration and hematogenous dissemination. It promotes cancer progression via adhesion, inflammation, immune evasion, epigenetic remodelling and metastasis. Its effects on therapy response are tumour‐context dependent. Microbiome‐guided targeting may enable precision oncology.
Feng Zhao, Rui An, Shaobo Yu, Yilei Ma, Wangwang Liu, Caixia Sheng, Xinyou Xie, Jun Zhang   +7 more
wiley   +1 more source

miR‐941 in extracellular vesicles confers anlotinib resistance via Keap1/Nrf2 axis and represents a therapeutic target in non‐small cell lung cancer

Clinical and Translational Medicine, Volume 16, Issue 6, June 2026.
EV‐derived miR‐941 as a key driver of anlotinib resistance via the Keap1/Nrf2 pathway represent a promising non‐invasive predictive biomarker and a potential therapeutic target for overcoming resistance in NSCLC. Abstract Background Anlotinib is a multitargeted tyrosine kinase inhibitor for the treatment of advanced non‐small cell lung cancer (NSCLC ...
Aimi Huang, Xiaoqi Li, Erpeng Wu, Menglan Hao, Weimin Wang, Jinjing Xia   +5 more
wiley   +1 more source

PET/CT and PET/MRI in Cancer Diagnosis and Management: A Comparative Clinical Perspective

iMetaMed, Volume 2, Issue 2, June 2026.
This review compares PET/CT and PET/MRI in cancer imaging, highlighting their complementary roles for precise diagnosis and staging. It evaluates their technical strengths, clinical performance across various cancers, and future directions, including AI and novel tracers.
Zijian Ding, Ran Xue, Qianxi Jin, Wangzheqi Zhang, Yali Wu, Baixuan Xu   +5 more
wiley   +1 more source

Exosomal Oleic Acid Promotes Lymphangiogenesis and Nodal Metastasis in Cervical Cancer via the AKT/mTOR Pathway

Journal of Extracellular Vesicles, Volume 15, Issue 6, June 2026.
Cervical cancer exosomes deliver SCD‐dependent oleic acid to LECs, activating AKT/mTOR to drive VEGF‐independent lymphangiogenesis and nodal metastasis, identifying exosomal OA as a therapeutic target. ABSTRACT Cervical cancer (CC) exhibits a pronounced tropism for regional lymphatic dissemination, a process driven by tumor‐associated lymphangiogenesis.
Jinqiu Li, Xiaojing Huang, Guzhalinuer Abulizi, Ayshamgul Hasim   +3 more
wiley   +1 more source

Two novel ligand-independent variants of the VEGFR-1 receptor are expressed in human testis and spermatozoa, one of them with the ability to activate SRC proto-oncogene tyrosine kinases. [PDF]

Oncotarget, 2019
Alvarez-Palomo B, Barrot-Feixat C, Sarret H, Requena J, Pau M, Vidal-Taboada JM, Oliva R, Ballesca JL, Edel MJ, Mezquita-Pla J.   +9 more
europepmc   +1 more source

Regulation of Immune Checkpoints: From Molecular Mechanisms to Clinical Therapies

MedComm, Volume 7, Issue 6, June 2026.
Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment by unleashing antitumor immunity. This review comprehensively examines the molecular mechanisms underlying key immune checkpoints—including PD‐1/PD‐L1, CTLA‐4, and TIM‐3—and their clinical applications.
Qintao Ge, Liu Yu, Jiahe Lu, Aihetaimujiang Anwaier, Xiyue Xiao, Yonghao Chen, Dingwei Ye, Hailiang Zhang, Wenhao Xu, Wenbin Dai   +9 more
wiley   +1 more source

Gastric Cancer: Pathobiology and Therapeutics

MedComm, Volume 7, Issue 6, June 2026.
Gastric cancer is a multistep process driven by the interplay of microbial virulence, host epithelial injury, and evolving molecular reprogramming. Initiation involves pathogen‐induced epigenetic alterations and the early subversion of key oncogenic signaling networks, facilitating the transition from chronic injury to metaplasia and malignant ...
Ruixian Yu, Miao Zhang, Yan Meng, Chunxiao Zhu, Weihong Zhang, Hui Zhang, Zhifa Cao, Meihang Du, Zhangting Zhao, Junping Bai, Yi Han, Yang Tang, Wei Kang, Ka Fai To, Shi Jiao, Liwei An, Zhaocai Zhou   +16 more
wiley   +1 more source